Skip to main content

Kiniksa Pharmaceuticals International, plc

KNSA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001730430

In the last 90 days, Kiniksa Pharmaceuticals International, plc insiders filed 0 open-market purchases and 2 sales; 267 institutions reported holding it in 13F filings for Q2 2026, worth $2.99B in total; no superinvestor holds it.

Q1 2022 vs. Q4 2021

How the institutions holding Kiniksa Pharmaceuticals International, plc changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of KNSA: Q4 2021 compared with Q1 2022
MeasureQ4 2021Q1 2022Change
Holders10396−7
Shares29.4M30.8M+1.35M (+4.6%)
Value$346.4M$306.0M−$40.4M (−11.7%)

New holders (13)

Institutions that held Kiniksa Pharmaceuticals International, plc at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to KNSA in Q1 2022
InstitutionSharesValue% of portfolio
Tang Capital Management LLC500,000$4.97M1.01%
PDT Partners, LLC66,276$659.0K0.06%
HRT Financial LP58,874$585.0K0.00%
Waldron Private Wealth LLC37,696$374.0K0.02%
Jane Street Group, LLC22,731$226.0K0.00%
State of Wisconsin Investment Board21,100$210.0K0.00%
Amalgamated Bank4,093$41.0K0.00%
US Bancorp610$6.00K0.00%
National Bank of Canada500$5.00K0.00%
Carmichael Hill & Associates, Inc.248$2.00K0.00%
Aquatic Capital Management LLC200$2.00K0.00%
Signaturefd, LLC57$1.00K0.00%
Advisor Group Holdings, Inc.100$1.00K0.00%

Sold out (20)

Institutions that held Kiniksa Pharmaceuticals International, plc at the end of Q4 2021 and filed for Q1 2022 without it.